Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies (Abstract #749)
Abstract details are now available.
https://meetings.asco.org/abstracts-presentations/229209
Background:
CF33-hNIS is a novel chimeric DNA vaccinia virus engineered with the human sodium-iodide symporter (hNIS) gene. CF33-hNIS selectively replicates in tumor cells leading to cell lysis and the release of tumor- and virus-associated antigens stimulating antitumor immunity. Here, we report results of patients with GI malignancies enrolled on a first-in-human phase 1 ascending, multiple dose, safety and tolerability study of CF33-hNIS, administered intratumorally (IT) or intravenously (IV) in adult patients with metastatic or advanced solid tumors (MAST).
Methods:
The MAST study is evaluating the safety of CF33-hNIS administered IT or IV, alone or in combination with pembrolizumab in patients with advanced or metastatic solid tumors with ≥ 2 prior lines of therapy (NCT05346484). CF33-hNIS is administered in 21-day cycles on C1D1 and C1D8, then D1 of each cycle thereafter. Pembrolizumab begins C2D1 for the combination groups and is administered Q3W. The co-primary endpoints are safety and to identify the recommended phase 2 dose. Secondary endpoints include objective response rate according to RECIST v1.1 and iRECIST, and to assess levels of viral replication via Single-Photon Emission Computerized Tomography (SPECT) with technetium-99.
Results:As of Aug 2023, we report early results from seven patients with GI malignancies who received CF33-hNIS alone, including: colorectal cancer (3), bile duct (2), pancreatic (1) and hepatocellular carcinoma (1). The disease control rate is 86%. Notably one patient with cholangiocarcinoma, treated IT with 3.0x107 PFU, presented with pseudoprogression with a 49% increase in tumor burden after two cycles of therapy. By the 4th cycle they achieved a complete response (CR) with no known recurrence. A second patient with bile duct cancer, who previously progressed on checkpoint blockade therapy, achieved stable disease for >5 months upon receiving IV-administered CF33-hNIS (3.0x107 PFU). Treatment-related adverse events for the CR patient included grade 1 fever and injection site reaction. All other patients experienced no treatment-related adverse events. SPECT analysis of the CR patient reveals intense levels of viral replication within the injected lesion and a concomitant increase in Th1 cytokines in cycle three that coordinated with tumor reduction. In-depth immunological changes in peripheral blood and on-treatment tumor biopsies will be presented.
Conclusions:
CF33-hNIS can replicate within cholangiocarcinoma lesions, as shown by SPECT imaging, and drive immunological changes known to promote antitumor immunity. CF33-hNIS monotherapy may be an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, a rare disease with an unmet medical need. Treatment with CF33-hNIS monotherapy was well tolerated and the study has advanced to examine combination therapy with pembrolizumab. Clinical trial information: NCT05346484.
.
- Forums
- ASX - By Stock
- Why IMU is a multi multi bagger
Oncolytic virus CF33-hNIS monotherapy for the treatment of...
-
- There are more pages in this discussion • 4,667 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M |
Open | High | Low | Value | Volume |
5.5¢ | 5.6¢ | 5.3¢ | $537.6K | 10.00M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 207796 | 5.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 1452903 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 207796 | 0.053 |
16 | 1716454 | 0.052 |
17 | 1803686 | 0.051 |
38 | 2900313 | 0.050 |
37 | 5190186 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 1452903 | 6 |
0.055 | 1569444 | 6 |
0.056 | 1106444 | 10 |
0.057 | 1156345 | 6 |
0.058 | 1098372 | 6 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |